Stock MANGALAM MANGALAM DRUGS & ORGANICS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Mangalam Drugs & Organics Limited

Equities

MANGALAM

INE584F01014

Pharmaceuticals

Market Closed - Bombay S.E.
Other stock markets
 06:00:51 2024-05-31 EDT 		5-day change 1st Jan Change
101.6 INR +0.54% Intraday chart for Mangalam Drugs & Organics Limited -5.31% +3.52%
02-13 Mangalam Drugs & Organics Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
2023 Mangalam Drugs & Organics Limited Reports Earnings Results for the Half Year Ended September 30, 2023 CI

Valuation

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Capitalization 1 2,567 872.9 480.4 1,573 1,628 1,549
Enterprise Value (EV) 1 3,235 1,488 983.8 2,264 2,487 2,407
P/E ratio 12.9 x -10.9 x 5.83 x 5.63 x 8.28 x 122 x
Yield 0.31% - - - - -
Capitalization / Revenue 0.92 x 0.38 x 0.17 x 0.41 x 0.36 x 0.42 x
EV / Revenue 1.16 x 0.65 x 0.35 x 0.6 x 0.56 x 0.65 x
EV / EBITDA 6.9 x 15.5 x 4.35 x 4.34 x 5.65 x 9.99 x
EV / FCF -66.4 x 13.6 x 5.05 x -8.49 x -10.4 x -54.9 x
FCF Yield -1.51% 7.33% 19.8% -11.8% -9.58% -1.82%
Price to Book 2.44 x 0.91 x 0.46 x 1.2 x 1.08 x 1.02 x
Nbr of stocks (in thousands) 15,828 15,828 15,828 15,828 15,828 15,828
Reference price 2 162.2 55.15 30.35 99.40 102.8 97.85
Announcement Date 18-09-06 19-08-30 20-09-02 21-09-02 22-09-02 23-09-06
1INR in Million2INR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2018 2019 2020 2021 2022 2023
Net sales 1 2,794 2,276 2,824 3,801 4,476 3,702
EBITDA 1 468.7 95.76 226.1 521.9 440.6 241.1
EBIT 1 404.6 27.99 158.1 445.5 355 146.3
Operating Margin 14.48% 1.23% 5.6% 11.72% 7.93% 3.95%
Earnings before Tax (EBT) 1 293.5 -57.37 62.52 395.2 277.3 22.14
Net income 1 198.9 -80.31 82.52 279.7 196.6 12.7
Net margin 7.12% -3.53% 2.92% 7.36% 4.39% 0.34%
EPS 2 12.57 -5.074 5.210 17.67 12.42 0.8000
Free Cash Flow 1 -48.71 109 194.9 -266.7 -238.3 -43.82
FCF margin -1.74% 4.79% 6.9% -7.02% -5.32% -1.18%
FCF Conversion (EBITDA) - 113.83% 86.21% - - -
FCF Conversion (Net income) - - 236.2% - - -
Dividend per Share 2 0.5000 - - - - -
Announcement Date 18-09-06 19-08-30 20-09-02 21-09-02 22-09-02 23-09-06
1INR in Million2INR
Estimates

Balance Sheet Analysis

Fiscal Period: Maart 2018 2019 2020 2021 2022 2023
Net Debt 1 668 615 503 691 859 859
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 1.426 x 6.418 x 2.227 x 1.324 x 1.951 x 3.561 x
Free Cash Flow 1 -48.7 109 195 -267 -238 -43.8
ROE (net income / shareholders' equity) 20.8% -8.05% 8.27% 23.8% 14% 0.84%
ROA (Net income/ Total Assets) 11.9% 0.8% 4.47% 11.3% 7.49% 2.66%
Assets 1 1,673 -10,007 1,846 2,479 2,625 477.7
Book Value Per Share 2 66.50 60.50 65.70 82.70 95.10 96.00
Cash Flow per Share 2 0.2700 0.9100 1.030 0.3700 1.230 1.700
Capex 1 160 66.9 69.3 314 277 279
Capex / Sales 5.73% 2.94% 2.46% 8.27% 6.18% 7.54%
Announcement Date 18-09-06 19-08-30 20-09-02 21-09-02 22-09-02 23-09-06
1INR in Million2INR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Generic Pharmaceuticals

1st Jan change Capi.
MANGALAM DRUGS & ORGANICS LIMITED Stock Mangalam Drugs & Organics Limited
+3.52% 19.28M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+15.91% 41.97B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+22.40% 22.34B
SANDOZ GROUP AG Stock Sandoz Group AG
+18.48% 15.25B
CIPLA LIMITED Stock Cipla Limited
+16.12% 14B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+45.12% 12.06B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-9.58% 6.8B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+14.18% 5.49B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. MANGALAM Stock
  4. Financials Mangalam Drugs & Organics Limited